An observational study in Gilles de la Tourette Syndrome and Tourette Syndrome, sponsored by Max Planck Institute for Human Cognitive and Brain Sciences. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-29.
Sponsored by Max Planck Institute for Human Cognitive and Brain Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Tourette Syndrome with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Tourette Syndrome · Germany.
Among the 21 studies in Tourette Syndrome with a site in Germany, this one is one of 2 that started in 2022, is one of 2 observational ones, and was the 18th registered.
240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.
Browse Tourette Syndrome studies →1 of the 21 studies in Tourette Syndrome with a site in Germany is open now. Recruiting first, the newest first:
Neurothera Labs Inc. · Sites in Germany, United States, Israel
Ages 18–65
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 7
First in 2008; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is close to the median of 60 across 46 observational studies indexed under Tourette Syndrome.
Median enrollment 98 across the 19 interventional studies, 53 across the 2 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 21 have an industry lead sponsor. The 10 most frequent:
Max Planck Institute for Human Cognitive and Brain Sciences is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Max Planck Institute for Human Cognitive and Brain Sciences has 2 studies filed under Tourette Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Tourette Syndrome with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05126888Neurothera Labs Inc.SCI-110 in the Treatment of Tourette Syndrome | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Tourette Syndrome with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Gilles de la Tourette syndrome (GTS; also known as Tourette syndrome) is a congenital neuropsychiatric disorder. Characteristic symptoms are so-called tics-rapid, repetitive movements (motor tics) or vocalizations (vocal tics) that start suddenly without any apparent purpose. Previous research supports the hypothesis of defective regulation (dysregulation) of the dopaminergic system, with particular discussion of dysfunction of tonic/phasic dopamine release or dopaminergic hyperinnervation. Moreover, given the complex interaction of different neurotransmitters, especially in the basal ganglia, it can be assumed that abnormal dopaminergic transmission also affects other transmitter systems, such as glutamate (Glu) or γ-aminobutyrate (GABA). Furthermore, recent results suggest an abnormality in cerebral iron metabolism in GTS. Since iron is accumulated in dopamine vesicles and plays a central role in dopamine synthesis, this observation may also be related to dysfunction of the dopaminergic system. Therefore, in this multimodal study, the investigators aim to combine positron emission tomography (PET), magnetic resonance imaging (MRI), and magnetic resonance spectroscopy (MRS) methods comparing patients with GTS and a control cohort.
In Part 2 of this study, MRI and MRS at 7 Tesla are employed to investigate (i) the concentrations of Glu, glutamine and GABA in the corpus striatum and the cortex cingularis anterior and (ii) the subcortical iron concentration.
State of the Art
Gilles de la Tourette Syndrome (GTS) is characterized by the presence of motor and vocal tics, which have been defined as rapid, habitual, burst-like movements or utterances that typically mimic fragments of normal behavior. Patients often report unpleasant premonitory urge sensations preceding tics that are relieved by their execution. Although the therapeutic spectrum for GTS has recently been expanding, current treatment strategies are often unsatisfactory, thus provoking the need for further elucidation of the underlying pathophysiology.
In current models of GTS pathophysiology, symptoms are thought to arise as a result of the inappropriate activation of specific clusters of striatal neurons, which lead to a burst-like disinhibition of thalamocortical output. The bulk of current literature suggests a dysregulated dopaminergic system. This is supported by clinical evidence of improvements in tics following the administration of dopamine antagonists, synthesis blockers or depletion drugs, and the exacerbation of symptoms following the administration of dopaminergic stimulants. Dopamine drives movement by activating a direct, net excitatory basal ganglia pathway involving the dopamine receptor D1 or an indirect, net inhibitory basal ganglia pathway involving the dopamine receptor D2. Currently, the vast majority of the antipsychotics used for the treatment of tics in GTS aim at the D2 receptor, with aripiprazole, risperidone and pimozide being selective D2 receptor antagonists and haloperidol being mainly a D2 receptor antagonist. However, recent randomized controlled trials further indicate promising results for the selective dopamine receptor D1 antagonist ecopipam.
Methodologically varied work has revealed that patients with GTS exhibit alterations in (i) D2 receptor density or binding, (ii) Dopamine Active Transporter (DAT) density/binding, and (iii) phasic dopamine transmission in striatal and cortical regions. A very small number of post-mortem examinations further suggest potential abnormalities in D1 (and D2 and DAT) receptor densities in cortical regions. While this would be in line with the therapeutic efficiency of selective D1 receptor antagonists, thorough experimental verification is missing. In particular, D1 receptors in GTS patients have not yet been investigated in vivo, suggesting a need for additional research.
Both postsynaptic and presynaptic mechanisms have been postulated to offer explanations of the above observations:
Apart from such considerations specific to dopamine one can postulate that if a dopaminergic abnormality were present, other neurotransmitter systems would exhibit perturbations as well. In particular, this is suggested by (i) the close synergy exhibited between excitatory, inhibitory and modulatory neurotransmitter systems within the striatum and throughout the brain; and (ii) the interdependent metabolic relationship exhibited between glutamate (Glu), and γ-aminobutyric acid (GABA) via the non-neuroactive metabolic intermediate glutamine (Gln). Moreover, an irregular afferent modulation of dopaminergic nuclei would have profound effects on tonic/phasic dopaminergic release in the striatum and the control of subsequent thalamocortical output. Consistently, separate groups have demonstrated that adult patients with GTS exhibit alterations within the GABAergic system in cortical regions using in vivo proton (1H) magnetic resonance spectroscopy (MRS) and subcortical regions using PET. Employing 1H MRS, the investigators recently found reductions in striatal concentrations of Gln and the sum of Glu plus Gln (Glx) in GTS patients as well as negative correlations between striatal Gln and actual tic severity and between thalamic Glu and premonitory urges. While these findings do not rule out alternative mechanisms, they lend support to the hypothesis of an alteration in the dynamics of the tonic/phasic dopaminergic signaling because chronic perturbations in the subcortical GABA-Glu-Gln cycle flux could lead to spatially focalized alterations in excitatory and inhibitory neurotransmitter ratios.
Another aspect of dopamine neurobiology that has recently gained interest in the context of neuroimaging is the relation to brain iron. Besides supporting myelination and cellular respiration, brain iron is crucial for the synthesis of neurotransmitters, in particular dopamine. It is stored primarily as ferritin and co-localizes with dopamine vesicles having the greatest concentration in the dopamine-rich basal ganglia and midbrain. As the major brain iron compounds have (super)paramagnetic properties, they can be detected via susceptibility-sensitive magnetic resonance (MR) techniques, such as quantitative susceptibility mapping (QSM) or measurements of the effective or the reversible transverse relaxation rates, R2* or R2', respectively. Recent multimodal imaging targeted at (normal) developmental changes of the striatal dopamine system demonstrated that R2'-based estimates of tissue iron content were associated with carbon-11 [11C]dihydrotetrabenazine PET of presynaptic vesicular dopamine. This suggests that susceptibility-sensitive MR imaging (MRI), which does not require an intravenously applied radiotracer, might serve as a proxy for obtaining information on dopamine that could substitute measurements of HVA in CSF without sharing the same confounds. More recently, the investigators already obtained preliminary indications of disturbed iron homeostasis in GTS patients as evidenced by reduced serum ferritin and magnetic susceptibility in the striatum and further subcortical structures.
Objectives and Hypotheses
In continuation of previous investigations, the investigators plan to perform examinations with MRI and MRS in GTS patients in comparison to age- and sex-matched healthy controls within Part 2 of this combined study. This includes (indirect) information on the interplay of different neurotransmitter systems (Glu, and GABA), as well as on the role of brain iron in GTS.
In particular, the investigators plan to use (i) iron-sensitive MRI techniques, such as QSM and R2* mapping; and (ii) 1H MRS with standard single-voxel techniques and spectral-editing methods, for obtaining neurochemical profiles and quantitative information on Glu, Gln, and GABA in the striatum and cortical areas.
Neuropsychological tests:
At the time of the MR and/or PET exams, an established, comprehensive test battery will be performed with all patients for a detailed clinical assessment, including the severity of tics or the presence of comorbidities. These tests may be performed online as a video conference questionnaire and include:
MR exams within Part 2 (7T MR):
MR scanning at 7 Tesla will be performed to exploit the increased sensitivity available at the higher magnetic field. In particular, this will improve the sensitivity of susceptibility-sensitive MR techniques, which permits to achieve sub-millimeter spatial resolutions for better segmentation of small subcortical structures, such as the subtantia nigra, subthalamic nucleus or red nucleus. Similarly, improved sensitivity and spectral resolution at 7 T will expand the range of accessible metabolites, which allows reliable separation of Glu and Gln as well as improved detectability of GABA. The 7T sub-study comprises the following acquisitions:
Single-voxel proton MRS of the basal ganglia and anterior cingulate cortex with both direct and edited acquisitions to obtain concentration estimates of local Glu, Gln, and GABA.
10ml of venous blood will be collected from all subjects (GTS patients and healthy controls) at the time of the exam for subsequent measurement of blood ferritin levels. These levels will be compared with the results from susceptibility-related measures of brain iron.
GTS group selected from primary care clinic and by advertisement in GTS patient organizations Control group selected from database of the MPI and advertisement
GTS Group:
Inclusion Criteria:
Exclusion Criteria:
Control Group:
Inclusion Criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort of adult GTS patients, males and females, age range 18 to 50 years
Device: MRI scanner (7 Tesla)
Cohort of healthy control subjects, males and females, age range 18 to 50 years
Device: MRI scanner (7 Tesla)
MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min
Subcortical magnetic susceptibility as brain iron proxy
Iron stores in subcortical structures are changed in GTS patients
Time frame: Susceptibility is measured through study completion, an average of 6 months
Effective transverse relaxation rate, R2*, as brain iron proxy
R2\* in subcortical structures is changed in GTS patients
Time frame: R2* is measured through study completion, an average of 6 months
Concentration of glutamate (Glu) and glutamate plus glutamine (Glx)
Glu and Glx levels are changed in GTS patients in striatum and cingulate cortex
Time frame: Glu and Glx are measured through study completion, an average of 6 months
Concentration of glutamine (Gln)
Gln levels are changed in GTS patients in striatum and cingulate cortex
Time frame: Gln is measured through study completion, an average of 6 months
Concentration of γ-aminobutyrate (GABA)
GABA levels are changed in GTS patients in striatum and cingulate cortex
Time frame: GABA is measured through study completion, an average of 6 months
Plasma ferritin level
Blood ferritin is changed in GTS patients
Time frame: A plasma sample is analyzed through study completion, an average of 6 months
Plan to share: Undecided
Ran from Jan 2022 to primary completion in Apr 2023, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Max Planck Institute for Human Cognitive and Brain Sciences